ChroMedX Appoints Dr. Robert Smyth to Technical Advisory Board
March 24, 2015
ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the appointment of anesthesiologist Dr. Robert Smyth to the Company’s Technical Advisory Board.
Dr. Smyth completed his MD from the University of Calgary and his anesthesia residency at the University of Toronto. He is an anesthesiologist at Southlake Regional Health Centre in Newmarket, Ontario. In addition he is an Adjunct you did your Assistant Professor at McMaster University Department of Anesthesia and a lecturer at the University of Toronto Department of Anesthesiology. While his time is spent predominantly in clinical medicine, his particular field of interest is cardiorespiratory medical and critical care.
“We are pleased to have someone with the experience and expertise of Dr. Smyth, join our Technical Advisory Board. His professional knowledge and research interests add another dynamic to the Company’s maturing Technical Advisory Board and will be essential to the development of the Company’s HemoPalm technology”, said Dr. Maddever.
Dr. Smyth said, “The HemoPalm system will have significant advantages in the operating and recovery rooms, emergency departments and also by auxiliary medical personnel in the field”
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com